Sitagliptin/Metformin Pharmacare 50 mg/850 mg film-coated tablets 马耳他 - 英文 - Malta Medicines Authority

sitagliptin/metformin pharmacare 50 mg/850 mg film-coated tablets

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Sitagliptin/Metformin Pharmacare 50 mg/1000 mg film-coated tablets 马耳他 - 英文 - Malta Medicines Authority

sitagliptin/metformin pharmacare 50 mg/1000 mg film-coated tablets

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Sitagliptin Pharmacare 100 mg film-coated tablets 马耳他 - 英文 - Malta Medicines Authority

sitagliptin pharmacare 100 mg film-coated tablets

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 100 mg - drugs used in diabetes

CLINOLEIC 20 % 以色列 - 英文 - Ministry of Health

clinoleic 20 %

remedix care ltd - olive oil; soya oil - emulsion for infusion - olive oil 80 %; soya oil 20 % - oil - oil - source of lipids during parenteral nutrition in situations where oral or enteral feeding is impossible, insufficient or contra-indicated.

ORKAMBI 150/188 lumacaftor/ivacaftor 150mg/188mg granules sachet 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

orkambi 150/188 lumacaftor/ivacaftor 150mg/188mg granules sachet

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 150 mg; ivacaftor, quantity: 188 mg - granules - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; hypromellose acetate succinate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

ORKAMBI 100/125 lumacaftor/ivacaftor 100mg/125mg granules sachet 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

orkambi 100/125 lumacaftor/ivacaftor 100mg/125mg granules sachet

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 100 mg; ivacaftor, quantity: 125 mg - granules - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; hypromellose acetate succinate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Influvac sub-unit, suspension for injection (influenza vaccine, surface antigen, inactivated) 马耳他 - 英文 - Malta Medicines Authority

influvac sub-unit, suspension for injection (influenza vaccine, surface antigen, inactivated)

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - a, guangdong, maonan, swl, hong kong, b, washington - suspension for injection in pre-filled syringe - a/guangdong-maonan/swl1536/2019 15 µg a/hong kong/2671/2019 15 µg b/washington/02/2019 15 µg - vaccines

ORKAMBI 75/94 lumacaftor/ivacaftor 75mg/94mg granules sachet 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

orkambi 75/94 lumacaftor/ivacaftor 75mg/94mg granules sachet

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 75 mg; ivacaftor, quantity: 94 mg - granules - excipient ingredients: croscarmellose sodium; hypromellose acetate succinate; microcrystalline cellulose; povidone; sodium lauryl sulfate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

ORKAMBI- lumacaftor and ivacaftor tablet, film coated
ORKAMBI- lumacaftor and ivacaftor granule 美国 - 英文 - NLM (National Library of Medicine)

orkambi- lumacaftor and ivacaftor tablet, film coated orkambi- lumacaftor and ivacaftor granule

vertex pharmaceuticals incorporated - lumacaftor (unii: egp8l81apk) (lumacaftor - unii:egp8l81apk), ivacaftor (unii: 1y740ill1z) (ivacaftor - unii:1y740ill1z) - lumacaftor 200 mg - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene. if the patient's genotype is unknown, an fda-cleared cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene. limitations of use the efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation. none. risk summary there are limited and incomplete human data from clinical trials and postmarketing reports on use of orkambi or its individual components, lumacaftor or ivacaftor, in pregnant women to inform a drug-associated risk. in animal reproduction studies, oral administration of lumacaftor to pregnant rats and rabbits during organogenesis demonstrated no teratogenicity or adverse effects on fetal development at doses that produced maternal exposures up to approximately 8 (rats) and 5 (rabbits) times the exposure at the maxim

HUMILAC DRY SKIN SPRAY AND RINSE OIL FREE HUMECTANT 澳大利亚 - 英文 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

humilac dry skin spray and rinse oil free humectant

allerderm - propylene glycol(106mg/ml)+urea(106mg/ml)+glycerol(79.5mg/ml) + others - topical aerosol spray - humectant - cat | dog | horse | laboratory animal | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | f - keratolytic or cleaning agent | biotin deficiency | brittle hoof | cleansing agents | coat appearance | conditioning | conjunctivitis | cracked hoof | dry skin | flaking | galls | grooming aids | hoof conditioning | hoof moisturising | hopple chafes | itching | laminitis | moisturising | pliability | psoriasis | scratches | skin cleanser | wart removal